1. 2017 Parkinson Disease

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. 2017 Parkinson Disease

5. NMS in Parkinson Disease Background

6. Clinical Markers of Prodromal PD

7. PD Risk Factors in the HPFS: Study Design

8. PD Risk Factors in the HPFS Results

9. PD Risk Factors in the US-Based AHS Study Design

10. PD Risk Factors in the US-Based AHS Results

11. Phosphorylated α-Synuclein As a PD Marker Study Design

12. Phosphorylated α-Synuclein As a PD Marker Results

13. Conclusions

14. 2017 Parkinson Disease

15. NINDS PD Risk Study Design

16. NINDS PD Risk Results

17. PMCA in PD Background and Participants

18. CONTENT NO LONGER AVAILABLE
PMCA in PD Results
PMCA detection of α- synuclein in CSF samples from patients with PD
Sensitivity: 88.5%
95% CI: 79.2%, 94.6%
Specificity: 96.9%
95% CI: 89.3%, 99.6%
α-Synuclein-PMCA correlations with PD clinical symptoms
Japanese cohort
rs = -0.54, P = .006
German cohort
rs = -0.36, P = .02
CONTENT NO LONGER AVAILABLE
Shahnawaz M, et al. JAMA Neurol. 2017;74:

19. BioFind Study Design

20. BioFind Results

21. BioFind Conclusions

22. 2017 Parkinson Disease

23. PPMI Study Design

24. PPMI Results

25. PPMI Conclusion

26. Guttuso Study Design

27. Guttuso Results

28. 2017 Parkinson Disease

29. GLORIA Study Design

30. GLORIA Results

31. Effects of LCIG on NMS Study Design

32. Effects of LCIG on NMS Results

33. TOLEDO Study Design

34. TOLEDO Results

35. 2017 Parkinson Disease

36. Background

37. BIIB054 Preclinical Findings

38. BIIB0054 Study Design

39. BIIB0054 Results

40. BIIB054 Ongoing Trial

41. PRX002 Preclinical Findings

42. PRX002 Study Design

43. PRX002 Results

44. PRX002 Ongoing Trial

45. VY-AADC01 Background

46. VY-AADC01: Study Design

47. VY-AADC01 Results

48. VY-AADC01 Ongoing Trial

49. Abbreviations

50. Abbreviations (cont)

51. Abbreviations (cont)

52. Abbreviations (cont)